Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.19.2
SEGMENT INFORMATION (Tables)
6 Months Ended
Apr. 30, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 

For the Six Months Ended

April 30,

 
 

 

2019

 

 

2018

Net loss:

         

Cancer Diagnostics

$

(3,052,355)

 

$

(1,362,451)

Cancer Therapeutics

 

(3,517,219)

   

(1,551,067)

Patent licensing

 

(971,969)

 

 

(344,470)

Total

$

(7,541,543)

 

$

(3,257,988)

           

Operating costs and expenses excluding non-cash

    share based compensation expense:

         

Cancer Diagnostics

$

1,417,967

 

$

1,075,480

Cancer Therapeutics

 

1,245,681

   

1,348,498

Patent licensing

 

1,091,700

 

 

1,002,879

Total

$

3,755,348

 

$

3,426,857

           

Operating costs and expenses excluding non-cash

    share based compensation expense

$

3,755,348

 

$

3,426,857

Plus non-cash share-based compensation expense

 

4,071,614

 

 

598,683

Total operating costs and expenses

$

7,826,962

 

$

4,025,540

For the Three Months Ended

April 30,

 

 

2019

 

 

2018

Net loss:

         

Cancer Diagnostics

$

(1,248,001)

 

$

(739,202)

Cancer Therapeutics

 

(1,029,934)

   

(442,049)

Patent licensing

 

(296,999)

 

 

(211,263)

Total

$

(2,574,934)

 

$

(1,392,514)

   

 

   

 

Operating costs and expenses excluding non-cash 

    share based compensation expense:

         

Cancer Diagnostics

$

658,433

 

$

549,866

Cancer Therapeutics

 

444,890

   

393,645

Patent licensing

 

418,461

 

 

875,733

Total

$

1,521,784

 

$

1,819,244

           

Operating costs and expenses excluding non-cash

    share based compensation expense

$

1,521,784

 

$

1,819,244

Plus non-cash share-based compensation expense

 

1,321,450

 

 

331,710

Total operating costs and expenses

$

2,843,234

 

$

2,150,954

           
 

  April 30,

2019

 

  October 31,

2018

   

Total assets:

         

Cancer Diagnostics

$

3,605,773

 

$

2,545,803

Cancer Therapeutics

 

2,939,717

   

2,157,359

Patent licensing

 

1,219,936

 

 

1,745,380

Total

$

7,765,426

 

$

6,448,542